Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 4/20 | 0.46 |
| ▸ | JAK1 | P23458 | 4/20 | 0.46 |
| ▸ | TYK2 | P29597 | 4/20 | 0.46 |
| ▸ | JAK3 | P52333 | 4/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25680363 | 0.82 | NPC1 (0.48) | HDAC1HDAC8JAK2JAK1TYK2 | |
| SCHEMBL25679715 | 0.81 | JAK2 (0.55) | HRH1HDAC1HDAC8JAK2JAK1 | |
| SCHEMBL25223841 | 0.78 | CCNK (0.51) | JAK3EGFRBTK | |
| SCHEMBL30533943 | 0.78 | CCNK (0.51) | JAK3EGFRBTK | |
| SCHEMBL25598176 | 0.70 | SMN1; SMN2 (0.54) | POLBNPC1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL25679696 | 0.68 | GLA (0.42) | NPC1KDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL30533876 | 0.68 | CDK12 (0.53) | JAK3EGFR | |
| SCHEMBL25218469 | 0.68 | HRH1 (0.45) | HRH1JAK2JAK1TYK2JAK3 | |
| SCHEMBL26630437 | 0.67 | RORC (0.54) | EGFR | |
| SCHEMBL25680537 | 0.67 | ALDH1A1 (0.69) | NPC1KDM4EALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203010-A1 | BICYCLIC AMINE CDK12 INHIBITORS | INCYTE CORPORATION | 2023-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203010-A1 | BICYCLIC AMINE CDK12 INHIBITORS | CDK12, CDK1, CDK2 | HRH1 3078/4885HDAC1 321/4885HDAC8 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.